Drug intelligence / Profile preview

cisplatin + oxaliplatin

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous

Overview

Cisplatin and oxaliplatin are platinum-based chemotherapy drugs that are sometimes used in combination for cancer treatment. Both drugs work by forming DNA crosslinks, particularly intrastrand and interstrand crosslinking, which interferes with DNA replication and leads to cell death. While they share similar mechanisms, oxaliplatin has a different chemical structure with a diamino cyclohexane (DACH) group that prevents cross-resistance with cisplatin. This combination may provide enhanced cell kill in certain cancer types, though it can also increase the risk of side effects.

Targets

DNA

Beyond the preview

Go deeper on cisplatin + oxaliplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + oxaliplatin.

Explore the full profile